Holen Sie sich die Stockscreener-App
19.00
5.49%
-1.12
Schlusskurs vom Vortag:
$20.12
Offen:
$20.02
24-Stunden-Volumen:
1.57M
Relative Volume:
2.56
Marktkapitalisierung:
$681.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-11.60%
1M Leistung:
+40.02%
6M Leistung:
+299.47%
1J Leistung:
+272.11%
1-Tages-Spanne:
$18.46
$20.02
1-Wochen-Bereich:
$18.46
$21.53
52-Wochen-Spanne:
$2.88
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
5885 HOLLIS STREET, EMERYVILLE
Vergleichen Sie BIOA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
19.01 | 721.40M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
124.02 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.96 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.90 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-21 | Eingeleitet | Citigroup | Buy |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
BioAge Labs edges down after stock sale hiked to $115 mln - TradingView — Track All Markets
BioAge Labs prices upsized public offering at $19.50 per share By Investing.com - Investing.com Nigeria
Fund Flows: Is BioAge Labs Inc in accumulation or distribution phase2025 Market WrapUp & Reliable Price Action Trade Plans - baoquankhu1.vn
BioAge Labs prices upsized public offering at $19.50 per share - Investing.com
Metabolic disease biotech BioAge raises $115M in stock sale - Stock Titan
BioAge Announces Pricing of Upsized $115.0 Million Public Offering - GlobeNewswire
Dow Update: Will SPDR Gold Trust benefit from rate cutsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Gap DownTime to Sell? - MarketBeat
Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
BioAge Announces Proposed $75 Mln Public Offering; Expands BGE-102 Development Into Ophthalmology - Nasdaq
BioAge Labs announces $75 million public stock offering By Investing.com - Investing.com Nigeria
BioAge expands BGE-102 program to diabetic macular edema By Investing.com - Investing.com India
BioAge Labs: Early-Stage Promise for BGE-102 Balanced by Long Timelines and Clinical Risk, Justifying Hold Rating - TipRanks
BioAge stock falls after announcing $75 million public offering By Investing.com - Investing.com UK
BioAge Labs announces $75 million public stock offering - Investing.com
BioAge Announces Proposed Public Offering - manilatimes.net
BioAge Announces Proposed Public Offering - Benzinga
BioAge Labs: Early-Stage NLRP3 Opportunity in Ophthalmology and Cardiometabolic Disease Warrants Neutral ‘Hold’ Amid Long Clinical Timelines - TipRanks
BioAge expanding indication for NLRP3 inhibitor BGE-102 into DME - The Pharma Letter
BioAge expands BGE-102 program to diabetic macular edema - Investing.com
BioAge Labs advances BGE-102 into ophthalmology clinical trials - TipRanks
BioAge Labs, Inc. Expands Indication for BGE-102 to Diabetic Macular Edema - TradingView — Track All Markets
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 - The Manila Times
Pill for diabetic eye swelling: BioAge tests oral alternative to eye injections - Stock Titan
BioAge Labs extends rally after updating early-stage trial data for lead drug - MSN
BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
BioAge Labs: Why Getting Into The Brain Might Be A Headache For Investors (NASDAQ:BIOA) - Seeking Alpha
The JPM Effect In Short Supply But BioAge And Bayer Gain - Citeline News & Insights
BioAge Labs (NASDAQ:BIOA) Shares Down 6.1% on Insider Selling - MarketBeat
Bioage Labs Inc (BIOA) Stock Price Down 5.15% on Jan 16 - GuruFocus
Insider Selling: CEO Kristen Fortney Sells Shares of Bioage Labs Inc (BIOA) - GuruFocus
Insider Selling: BioAge Labs (NASDAQ:BIOA) CEO Sells 233,107 Shares of Stock - MarketBeat
Dov Md Goldstein Sells 27,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
Bioage Labs Insider Sold Shares Worth $4,223,036, According to a Recent SEC Filing - marketscreener.com
Bioage Labs Insider Sold Shares Worth $531,828, According to a Recent SEC Filing - marketscreener.com
BioAge Labs (NASDAQ:BIOA) Shares Up 7.1%Time to Buy? - MarketBeat
BioAge reports 86% reduction in inflammation markers with BGE-102 By Investing.com - Investing.com India
BioAge Labs (NASDAQ:BIOA) Reaches New 1-Year HighShould You Buy? - MarketBeat
BioAge stock soars 21% on positive data for inflammation drug By Investing.com - Investing.com South Africa
BioAge stock soars 21% on positive data for inflammation drug - Investing.com
BioAge Labs advances BGE-102 with strong Phase 1 data - TipRanks
BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView — Track All Markets
BioAge announces additional positive interim phase 1 data for BGE-102, a novel brain-penetrant NLRP3 inhibitor, demonstrating potential for best-in-class hsCRP reduction in participants with elevated cardiovascular risk - marketscreener.com
Experimental pill sharply cuts heart inflammation in 2 weeks - Stock Titan
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with... - markets.businessinsider.com
Institutional investors are BioAge Labs, Inc.'s (NASDAQ:BIOA) biggest bettors and were rewarded after last week's US$51m market cap gain - simplywall.st
Weekly Earnings: Will The Chemours Company 2CU stock benefit from sector leadershipWeekly Trading Summary & Safe Capital Growth Plans - Bộ Nội Vụ
Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Reactions & Fast Exit Strategy with Risk Control - ulpravda.ru
Can BioAge Labs Inc. stock deliver sustainable ROERelative Strength Index (RSI) & Individual Stock Tracking Service - bollywoodhelpline.com
Aug Ideas: Will BioAge Labs Inc. stock maintain growth storyRate Hike & Target Return Focused Stock Picks - Улправда
How analysts rate BioAge Labs Inc. stock todayJuly 2025 News Drivers & Reliable Momentum Entry Alerts - Улправда
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Bioage Labs Inc-Aktie (BIOA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOLDSTEIN DOV A MD | Chief Financial Officer |
Jan 13 '26 |
Option Exercise |
8.39 |
27,000 |
226,530 |
49,408 |
| GOLDSTEIN DOV A MD | Chief Financial Officer |
Jan 13 '26 |
Sale |
19.70 |
27,000 |
531,828 |
22,408 |
| Fortney Kristen | Chief Executive Officer |
Jan 13 '26 |
Sale |
18.12 |
233,107 |
4,223,036 |
976,949 |
3.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):